ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer
Po-Li Wei, Chien-Yu Huang, Cheng-Chin Lee, Uyanga Batzorig, Kuei-Yen Tsai, Yu-Jia Chang · 2026
Read ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer by Po-Li Wei, Chien-Yu Huang, Cheng-Chin Lee, Uyanga Batzorig, Kuei-Yen Tsai, Yu-Jia Chang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13539918.txt.
Description
Po-Li Wei and five colleagues investigate, in a 2026 study, why some colorectal cancers with a faulty p53 gene resist the chemotherapy drug oxaliplatin. Attention falls on ALDH2, an enzyme best known for breaking down alcohol, whose levels run low in these tumors.
Using public tumor datasets and laboratory cell lines, the team showed that losing ALDH2 created resistance only when p53 was mutant. The loss raised a second enzyme, PDE4B, which matched poor outcomes in patients. A licensed drug that blocks PDE4B, roflumilast, restored the cancer cells' death response to oxaliplatin. The authors suggest testing this pairing in p53-mutant disease.
Catalog record
| CREATOR | Po-Li Wei, Chien-Yu Huang, Cheng-Chin Lee, Uyanga Batzorig, Kuei-Yen Tsai, Yu-Jia Chang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |